These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23437249)

  • 1. Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.
    Santoleri F; Sorice P; Lasala R; Rizzo RC; Costantini A
    PLoS One; 2013; 8(2):e56813. PubMed ID: 23437249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
    Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
    Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
    Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
    Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
    Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
    Griffin JD; Guerin A; Chen L; Macalalad AR; Luo J; Ionescu-Ittu R; Wu EQ
    Curr Med Res Opin; 2013 Jun; 29(6):623-31. PubMed ID: 23517347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
    Wei G; Rafiyath S; Liu D
    J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
    Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
    J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
    Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
    Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
    Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
    Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
    Cerrano M; Crisà E; Pregno P; Aguzzi C; Riccomagno P; Boccadoro M; Ferrero D
    Am J Hematol; 2013 Oct; 88(10):838-42. PubMed ID: 23757199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
    Quintas-Cardama A; Kantarjian H; Jones D; Nicaise C; O'Brien S; Giles F; Talpaz M; Cortes J
    Blood; 2007 Jan; 109(2):497-9. PubMed ID: 16990591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
    Goulden S; Sutcliffe F; Stevens A
    Lancet Oncol; 2012 Feb; 13(2):127-8. PubMed ID: 22403810
    [No Abstract]   [Full Text] [Related]  

  • 15. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
    Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New strategies in controlling drug resistance in chronic myeloid leukemia.
    Frame D
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
    Erba HP; Pham DC; Zaiden R; Vu H; Tai S
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life.
    Santoleri F; Ranucci E; La Barba G; Colasanto I; Scaldaferri M; Cattel F; Federici F; Rossi C; Di Biagio K; Scortechini AR; Musicco F; Torquati G; Frazzetto A; Vozza A; de Rosa C; Lanzillo R; Monteverde M; Luciano L; Pane F; Pasquazi A; Celeste MG; Cantonetti M; Franceschini L; Rizzo M; Costantini A
    Curr Med Res Opin; 2021 Mar; 37(3):477-481. PubMed ID: 33459083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
    Quintás-Cardama A; Cortes JE; O'Brien S; Ravandi F; Borthakur G; Liu D; Bleickardt E; Chen TT; Kantarjian HM
    Cancer; 2009 Jul; 115(13):2912-21. PubMed ID: 19402171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.